NASDAQ:GMAB - Genmab A/S Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $42.67
  • Forecasted Upside: 38.39 %
  • Number of Analysts: 15
  • Breakdown:
  • 2 Sell Ratings
  • 7 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$30.83
▼ -0.25 (-0.80%)

This chart shows the closing price for GMAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genmab A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GMAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMAB

Analyst Price Target is $42.67
▲ +38.39% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is $42.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 38.39% upside from the last price of $30.83.

This chart shows the closing price for GMAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 15 investment analysts is to hold stock in Genmab A/S. This rating has held steady since November 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 2 sell ratings
11/29/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 2 sell ratings
2/27/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 2 sell ratings
5/28/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 2 sell ratings
8/26/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 2 sell ratings
11/24/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 2 sell ratings
2/22/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 2 sell ratings
4/23/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 2 sell ratings
5/23/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2022Morgan StanleyLower Price TargetUnderweight$29.00Medium
5/13/2022Bryan, Garnier & CoUpgradeSell ➝ NeutralMedium
5/13/2022Berenberg BankUpgradeSell ➝ HoldMedium
5/2/2022CowenInitiated CoverageMarket Perform$38.00Low
5/2/2022CowenInitiated CoverageMarket PerformLow
4/12/2022Morgan StanleyLower Price TargetUnderweight$33.00 ➝ $30.00Low
3/17/2022HC WainwrightReiterated RatingBuy$47.00Medium
3/16/2022UBS GroupUpgradeNeutral ➝ BuyMedium
2/25/2022JPMorgan Chase & Co.Lower Price Target3,200.00 ➝ 3,100.00Low
2/17/2022SVB LeerinkLower Price TargetMarket Perform$42.00 ➝ $39.00High
1/31/2022HC WainwrightUpgradeNeutral ➝ Buy$47.00High
1/3/2022GuggenheimDowngradeBuy ➝ NeutralLow
12/1/2021Berenberg BankInitiated CoverageSellLow
9/20/2021HC WainwrightReiterated RatingHold$47.00Low
9/16/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$45.50 ➝ $48.00Low
9/7/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$37.00High
8/24/2021HC WainwrightDowngradeBuy ➝ Neutral$47.00Low
8/20/2021JPMorgan Chase & Co.Reiterated RatingOverweightMedium
8/16/2021Societe GeneraleReiterated RatingSellLow
8/12/2021BarclaysReiterated RatingOverweightLow
8/12/2021UBS GroupReiterated RatingNeutralLow
8/12/2021Royal Bank of CanadaBoost Price TargetOutperform$46.00 ➝ $55.00Medium
8/12/2021SVB LeerinkBoost Price TargetMarket Perform$37.00 ➝ $42.00Low
7/26/2021HC WainwrightReiterated RatingBuy$47.00Low
7/19/2021BarclaysReiterated RatingOverweightMedium
7/13/2021HC WainwrightReiterated RatingBuy$47.00Low
6/9/2021JPMorgan Chase & Co.Reiterated RatingOverweightMedium
6/7/2021UBS GroupReiterated RatingBuyLow
5/28/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
5/17/2021JPMorgan Chase & Co.Reiterated RatingOverweightLow
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuyLow
4/19/2021Morgan StanleyLower Price TargetEqual Weight$41.00 ➝ $37.00Low
3/15/2021DNB MarketsUpgradeSell ➝ BuyLow
3/9/2021JPMorgan Chase & Co.Reiterated RatingOverweightLow
3/9/2021UBS GroupReiterated RatingBuyLow
2/25/2021Truist FinancialBoost Price Target$42.00 ➝ $47.00Low
2/25/2021SVB LeerinkLower Price TargetMarket Perform$38.00 ➝ $36.00High
2/24/2021BarclaysReiterated RatingOverweightHigh
2/24/2021DanskeUpgradeHold ➝ BuyMedium
2/11/2021HC WainwrightReiterated RatingBuyLow
1/26/2021SVB LeerinkBoost Price TargetMarket Perform$34.00 ➝ $38.00Medium
1/25/2021DNB MarketsDowngradeHold ➝ SellMedium
1/19/2021Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
1/15/2021HC WainwrightBoost Price TargetBuy$44.00 ➝ $49.00High
1/4/2021Royal Bank of CanadaBoost Price TargetPositive ➝ Outperform$40.00 ➝ $46.00N/A
12/16/2020Morgan StanleyBoost Price TargetOverweight$37.00 ➝ $41.00Low
12/9/2020SVB LeerinkLower Price TargetMarket Perform$36.00 ➝ $34.00Medium
11/25/2020HC WainwrightLower Price TargetBuy$45.00 ➝ $44.00Low
11/16/2020UBS GroupReiterated RatingBuyLow
11/5/2020Morgan StanleyBoost Price TargetOverweight$35.00 ➝ $37.00Low
11/5/2020HC WainwrightBoost Price TargetBuy$42.00 ➝ $45.00Medium
10/27/2020The Goldman Sachs GroupBoost Price TargetNeutral$37.00High
10/13/2020Morgan StanleyBoost Price TargetOverweight$32.00 ➝ $35.00Low
9/23/2020HC WainwrightBoost Price TargetBuy$41.00 ➝ $42.00High
9/23/2020Bryan, Garnier & CoDowngradeNeutral ➝ SellHigh
9/8/2020SVB LeerinkInitiated CoverageMarket Perform$35.00Low
8/24/2020Truist FinancialBoost Price Target$39.00 ➝ $41.00Low
8/21/2020HC WainwrightBoost Price TargetBuy$40.00 ➝ $41.00Medium
8/13/2020Royal Bank of CanadaBoost Price TargetOutperform$35.00 ➝ $38.00Low
8/13/2020Morgan StanleyBoost Price TargetOverweight$30.00 ➝ $32.00High
8/13/2020HC WainwrightReiterated RatingBuyHigh
7/17/2020HC WainwrightReiterated RatingBuy$40.00Medium
7/2/2020Societe GeneraleInitiated CoverageSellLow
6/30/2020HC WainwrightReiterated RatingBuy$40.00Medium
6/25/2020Credit Suisse GroupDowngradeOutperform ➝ NeutralLow
6/19/2020Royal Bank of CanadaBoost Price TargetOutperform$27.00 ➝ $35.00Low
6/12/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
6/11/2020BarclaysReiterated RatingOverweightLow
6/11/2020SunTrust BanksBoost Price TargetBuy$36.00 ➝ $39.00Medium
6/11/2020HC WainwrightBoost Price TargetBuy$34.00 ➝ $40.00Medium
6/3/2020BarclaysReiterated RatingOverweightMedium
6/3/2020Bryan, Garnier & CoDowngradeBuy ➝ NeutralLow
6/2/2020SunTrust BanksBoost Price TargetBuy$30.00 ➝ $36.00Low
6/2/2020DanskeDowngradeBuy ➝ HoldLow
6/1/2020HC WainwrightReiterated RatingPositive ➝ Buy$29.00 ➝ $34.00Medium
5/26/2020UBS GroupUpgradeNeutral ➝ BuyLow
5/7/2020SunTrust BanksBoost Price TargetBuy$28.00 ➝ $30.00Low
5/7/2020HC WainwrightBoost Price TargetBuy$28.00 ➝ $29.00Low
5/1/2020HC WainwrightReiterated RatingBuy$28.00High
4/23/2020Credit Suisse GroupInitiated CoverageOutperformLow
4/15/2020Morgan StanleyLower Price TargetOverweight$31.00 ➝ $30.00Low
4/15/2020HC WainwrightLower Price TargetBuy$29.00 ➝ $28.00Low
4/6/2020Royal Bank of CanadaReiterated RatingBuy$27.00Medium
3/4/2020HC WainwrightReiterated RatingBuy$29.00Low
2/24/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $29.00Low
2/20/2020Morgan StanleyBoost Price TargetOverweight$30.00 ➝ $31.00Medium
2/11/2020HC WainwrightReiterated RatingBuy$25.00Medium
1/22/2020HC WainwrightReiterated RatingBuy$25.00Low
1/13/2020SunTrust BanksInitiated CoverageBuyMedium
12/12/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldHigh
12/11/2019HC WainwrightReiterated RatingBuy$25.00High
12/4/2019HC WainwrightReiterated RatingBuy$25.00Low
11/20/2019HC WainwrightReiterated RatingBuy$25.00Low
10/16/2019HC WainwrightBoost Price TargetBuy$24.00 ➝ $25.00Low
9/27/2019HC WainwrightSet Price TargetBuy$24.00Low
9/16/2019HC WainwrightReiterated RatingBuy$24.00Low
9/13/2019Bank of AmericaUpgradeNeutral ➝ BuyMedium
9/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$23.00Low
8/26/2019HC WainwrightReiterated RatingBuyLow
8/12/2019GuggenheimInitiated CoverageBuy ➝ BuyMedium
8/12/2019Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$23.00Low
8/12/2019Morgan StanleyInitiated CoverageOverweight ➝ OverweightLow
(Data available from 5/24/2017 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/26/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/25/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/25/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/24/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/23/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/25/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/24/2022

Current Sentiment

  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Genmab A/S logo
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: $30.83
Low: $30.73
High: $31.11

50 Day Range

MA: $34.60
Low: $27.98
High: $38.57

52 Week Range

Now: $30.83
Low: $27.42
High: $49.07

Volume

353,916 shs

Average Volume

655,968 shs

Market Capitalization

$20.27 billion

P/E Ratio

54.09

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Genmab A/S?

The following Wall Street sell-side analysts have issued reports on Genmab A/S in the last year: Barclays PLC, Berenberg Bank, Bryan, Garnier & Co, Cowen Inc, Cowen Inc., Deutsche Bank Aktiengesellschaft, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, Societe Generale, SVB Leerink LLC, TheStreet, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for GMAB.

What is the current price target for Genmab A/S?

0 Wall Street analysts have set twelve-month price targets for Genmab A/S in the last year. Their average twelve-month price target is $42.67, suggesting a possible upside of 38.4%.
View the latest price targets for GMAB.

What is the current consensus analyst rating for Genmab A/S?

Genmab A/S currently has 2 sell ratings, 7 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GMAB, but not buy more shares or sell existing shares.
View the latest ratings for GMAB.

How do I contact Genmab A/S's investor relations team?

Genmab A/S's physical mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The company's listed phone number is (457) 020-2728 and its investor relations email address is [email protected] The official website for Genmab A/S is www.genmab.com. Learn More about contacing Genmab A/S investor relations.